Kyle Hudgens
Neurology · Birmingham, ALNPI 1669475240
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 1,206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,223 and has fallen 82.7% since, to $732 in 2024.
Across 1,206 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novartis$2K
- Biogen$977
- Amgen$849
- Acorda Therapeutics, Inc$775
- MDD US Operations, LLC$770
- plus $11K from 53 others
What the payments were for
- Speaking & faculty fees$3622%
- Food & beverage$19,47598%
- Education$900%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GOCOVRI$579
How this compares
$19,927 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 12 | $101,674 |
| QuliptaAtogepant | 19 | $25,714 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $25,623 |
| XcopriCenobamate | 12 | $14,809 |
| NeuproRotigotine | 16 | $13,187 |
| Lacosamide | 41 | $10,023 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 41 | $9,030 |
| Rasagiline Mesylate | 16 | $6,916 |
| Galantamine ErGalantamine Hbr | 26 | $5,264 |
| Levetiracetam | 167 | $5,052 |
| Memantine Hcl | 119 | $2,889 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $2,884 |
| DilantinPhenytoin Sodium Extended | 13 | $2,499 |
| Rivastigmine | 14 | $2,102 |
| Carbamazepine | 24 | $1,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $977 | $101,67412 claims |
| AbbVieQulipta | $3,667 | $25,71419 claims |
| SK Life Science, Inc.Xcopri | $350 | $14,80912 claims |
| UCB, Inc.Neupro | $750 | $13,18716 claims |
| PfizerDilantin | $244 | $2,49913 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $232 | $1,26413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.